 |
144 Diseases |  |
5 Trials |
|
5 Trials |  |
837 News |  |
| «12345678» |
- |||| imetelstat (GRN163L) / Geron
#ASCO23 #mdssm Zeidan: Imetelstat well tolerated. Cytopenias common but manageable w holding drug. Reduction in mutation VAF seen on Imetelstat arm showing potential for disease course modification. Great work @Dr_AmerZeidan et al! (Twitter) - Jun 2, 2023
- |||| imetelstat (GRN163L) / Geron
Clinical: @Dr_AmerZeidan presenting imetelstat p3 trial in pts failed by ESA - loved emphasis on having 2 positive MDS trials in one session (at #ASCO23 to boot!) #mdssm - tolerability seems reasonable and would fill a significant unmet need (Twitter) - Jun 2, 2023
- |||| imetelstat (GRN163L) / Geron
Clinical, P3 data: Happening now at #ASCO23: @Dr_AmerZeidan of @Yale is presenting results from the phase III IMerge study, which evaluated imetelstat in certain patients with LR-MDS. (Twitter) - Jun 2, 2023
- ||||| imetelstat (GRN163L) / Geron
First author @Dr_AmerZeidan presents results of the Phase III study #IMerge today at 2:12pm CDT during the Hematologic Malignancies track. https://t.co/FSpNJbOcTP #ASCO23 #hematology #imetelstat @YaleHematology @SmilowCancer @YaleMed @YNHH @OncoAlert (Twitter) - Jun 2, 2023
- || imetelstat (GRN163L) / Geron
$GERN Imetelstat at #ASCO23 https://t.co/qj0aHbGTTg (Twitter) - Jun 2, 2023
- | imetelstat (GRN163L) / Geron
Journal: Telomerase-Targeted Therapies in Myeloid Malignancies. (Pubmed Central) - May 22, 2023
We go on to discuss the development of telomere and telomerase targeted therapeutic candidates within the realm of myeloid malignancies. We overview all mechanisms of targeting telomerase that are currently in development with a particular focus on imetelstat, an oligonucleotide with direct telomerase inhibitory properties that has advanced the furthest in clinical development and has demonstrated promising data in multiple myeloid malignancies.
- | imetelstat (GRN163L) / Geron, Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen, Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Journal: Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment. (Pubmed Central) - May 21, 2023
For higher-risk MDS patients, hypomethylating agent monotherapy continues to be the standard of care. However, with various novel hypomethylating agent-based combination therapies in advanced clinical testing and an increased emphasis on individualized biomarker-driven treatment decisions, the standard therapy paradigms might change in the future.
- | Rytelo (imetelstat) / Geron
Trial initiation date: IMpress: Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy (clinicaltrials.gov) - May 16, 2023
P2, N=46, Not yet recruiting, Sponsor: GCP-Service International West GmbH
However, with various novel hypomethylating agent-based combination therapies in advanced clinical testing and an increased emphasis on individualized biomarker-driven treatment decisions, the standard therapy paradigms might change in the future. Initiation date: Dec 2022 --> May 2023
- |||||| imetelstat (GRN163L) / Geron
Clinical: Title: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS #MDS #EHA23 EHA Library; Jun 08 2023; 387864 https://t.co/DStUd4ziRg (Twitter) - May 13, 2023
- || imetelstat (GRN163L) / Geron
Like a prehistoric imetelstat (Twitter) - May 12, 2023
- imetelstat (GRN163L) / Geron
A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF) () - May 12, 2023 - Abstract #EHA2023EHA_3058;
P3
The study is currently open for enrollment. Myelofibrosis, Telomerase activity, Therapy, Janus Kinase inhibitor
- imetelstat (GRN163L) / Geron, Jakafi (ruxolitinib) / Novartis, Incyte
AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF () - May 12, 2023 - Abstract #EHA2023EHA_3056;
P1
Phase 1 dose-escalation (Part 1) is open for enrollment at ?3 sites across North America, targeting ?41 pts. Telomerase activity, Myelofibrosis, Janus Kinase inhibitor, Therapy
- imetelstat (GRN163L) / Geron
DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3 (Hall Goldman) - May 12, 2023 - Abstract #EHA2023EHA_2470;
P2/3
Furthermore, SF3B1 VAF reduction correlated with clinically meaningful endpoints of increased hemoglobin and TI duration. These data, taken together with robust rates of TI that are continuous and durable, may indicate improvement of the ineffectiveerythropoiesis characteristic of LR-MDS and suggest imetelstat may alter the underlying biology of disease in these patients.
- imetelstat (GRN163L) / Geron
THE TELOMERASE INHIBITOR IMETELSTAT DIFFERENTIALLY TARGETS JAK2V617F- VERSUS CALR-MUTANT MYELOPROLIFERATIVE NEOPLASM CELLS AND INHIBITS JAK-STAT SIGNALING (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1257;
Although the exact patient population who will benefit most from imetelstat is still undefined, our data propose that CALR-mutated clones are highly vulnerable. Mutation analysis, Myeloproliferative disorder, Myeloid differentiation, Telomere length
- imetelstat (GRN163L) / Geron
ANALYSIS OF PATIENT-REPORTED FATIGUE IN IMERGE PH3 TRIAL OF IMETELSTAT VS PLACEBO IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES R/R TO ERYTHROPOIESIS STIMULATING AGENTS (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_993;
P2/3
After 12 wks, greater improvement in fatigue was reported with imetelstat compared to placebo; pts on imetelstat were more likely to have sustained meaningful improvement infatigue and quicker to experience it. A significant association between TI and HI-E responses and sustained meaningful improvement in fatigue support the clinical benefit of imetelstat treatment.
- imetelstat (GRN163L) / Geron
MODULATION OF THE IMMUNE LANDSCAPE IN LOWER-RISK MYELODYSPLASTIC SYNDROMES WITH IMETELSTAT-INDUCED TRANSFUSION INDEPENDENCY (Hall Boiron) - May 12, 2023 - Abstract #EHA2023EHA_927;
P2/3
Low inflammatory features at baseline and induction of an adaptive immune profile by imetelstat are associated with the TI response, suggesting that immune cell remodeling could contribute to hematopoietic activity of imetelstat treatment. Anemia, Immunomodulation, Telemore inhibitors, Myelodysplastic syndrome
- imetelstat (GRN163L) / Geron
CONTINUOUS TRANFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3 (Hall Boiron) - May 12, 2023 - Abstract #EHA2023EHA_923;
P2/3
For this LR-MDS patient population, almost one fifth of imetelstat-treated pts achieved continuous TI for ?1 yr, representing substantial relief from transfusion- associated complications. VAF reduction and its correlation to clinical endpoints, including durable TI, supportimetelstat's disease-modifying potential.
- imetelstat (GRN163L) / Geron
IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA). (Available On Demand) - Apr 26, 2023 - Abstract #ASCO2023ASCO_789;
P2/3
For this LR-MDS pt population, imetelstat demonstrated statistically significant and clinically meaningful efficacy with high 8- and 24-wk TI rates, prolonged TI duration and increased hemoglobin. VAF reduction and its correlation to clinical endpoints support imetelstat
- imetelstat (GRN163L) / Geron, Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen, Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Therapies of Anemia (Excluding MDS-RS Treatment) (Auditorium; Virtual) - Apr 25, 2023 - Abstract #MDS2023MDS_81;
Luspatercept, a TGFbeta family ligand-trap induces nearly 50% of RBC transfusion independence in MDS with ring sideroblasts ( RS), but it has been shown to be active also in transfusion dependent non-RS LR MDS both in first line and after failure of ESA treatment. The telomerase inhibitor imetelstat has shown efficacy and disease modifying activity in LR MDS ESA refractory or relapsed, who did not receive lenalidomide or hypomethylating agents...Another approach has been represented by the oral hypoxia
- |||| imetelstat (GRN163L) / Geron
Clinical: Here my idea, approval imetelstat. It clearly provides a clinical benefit, reduces blood transfusions, and kills cancer. $gern (Twitter) - Mar 27, 2023
- || imetelstat (GRN163L) / Geron, Reblozyl (luspatercept-aamt) / BMS, Merck (MSD), Inqovi (decitabine/cedazuridine) / Otsuka
Why the last? This chapter was written years ago, before the IPSS-M, before the 5th edition WHO, before the ICC, before important new biological and genetic discoveries, before luspatercept and ASTX727 approval, and potentially imetelstat soon. So it’s already partly obsolete. (Twitter) - Mar 4, 2023
- ||| imetelstat (GRN163L) / Geron
Trial completion date: IMerge: Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Feb 10, 2023
P2/3, N=278, Recruiting, Sponsor: Geron Corporation
The telomerase inhibitor imetelstat has shown efficacy and disease modifying activity in LR MDS ESA refractory or relapsed, who did not receive lenalidomide or hypomethylating agents...Another approach has been represented by the oral hypoxia Trial completion date: Oct 2023 --> Oct 2026
- ||||| Clinical, Review: Great review by @Dr_AmerZeidan about current options for MDS patients. Great news for LR-MDS with Luspatercept and Imetelstat. Still anxiously waiting results for HR-MDS and AZA/VEN in first line. https://t.co/stPmIsEDvB (Twitter) - Feb 7, 2023
- || imetelstat (GRN163L) / Geron
Imetelstat Godspeed $gern (Twitter) - Feb 3, 2023
- || imetelstat (GRN163L) / Geron
Imetelstat in Low-Risk MDS for Transfusion Independence: the Phase 3 IMerge Study by @LFletcherMD15 https://t.co/quD3qq2lIv @dipeshuprety4 (Twitter) - Jan 30, 2023
- | Journal: Advances in myelodysplastic syndromes: promising novel agents and combination strategies. (Pubmed Central) - Jan 10, 2023
These advances will hopefully bring better treatment options to patients and lead to a shift in the treatment paradigm. Post HMA therapy remains an area of dire unmet need.
- || imetelstat (GRN163L) / Geron
Imetelstat 👏 (Twitter) - Jan 7, 2023
- |||| imetelstat (GRN163L) / Geron
P3 data: @DavidSteensma @hemedoc @smbenlazar @Abdallah81MD @Dr_AmerZeidan @MDS_Hub @MikkaelSekeres @Abdallah81MD @aamdsif @amitvermamds #mdssm @HemeOncBuddy @DrChoueiri @AliTaherMD @felrassi @DrJCornago @garciamanero @drhedrick @teamhaem Thoughts on IMerge phase 3 data for imetelstat? (Twitter) - Jan 4, 2023
- ||||| imetelstat (GRN163L) / Geron
Clinical, P3 data: top line: Geron Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS. Primary endpoint 8-week RBC transfusion independence (TI) and secondary endpoint 24-week RB TI appears to be met vs. placebo. #MDSsm #leusm #hematology https://t.co/U7le06maNK. (Twitter) - Jan 4, 2023
- ||| imetelstat (GRN163L) / Geron
Clinical, FDA event: Remember $GERN imetelstat went on clinical hold for liver tox in 2014 (Twitter) - Jan 4, 2023
- | imetelstat (GRN163L) / Geron
Good morning! First big catalyst of 2023 coming before the market opens today: $GERN Imerge trial of imetelstat in low/intermediate-risk MDS $BMY $INCY (Twitter) - Jan 4, 2023
- || imetelstat (GRN163L) / Geron
Moonshot $gern imetelstat redemption (Twitter) - Dec 31, 2022
- || imetelstat (GRN163L) / Geron
#Imetelstat in r/r #LR_MDS P2 study 👉🏻 29% TI 👉🏻⬇️ mutation burden Phase 3 study is accrued and pending results #MDSsm https://t.co/UKoIqEhxCe #ASH22 (Twitter) - Dec 11, 2022
- |||| imetelstat (GRN163L) / Geron
@UwePlatzbecker updating us on important follow-up data with prolonged responses to imetelstat in #MDSsm! #ASH22 @SylvesterCancer (Twitter) - Dec 11, 2022
- imetelstat (GRN163L) / Geron
Pharmacological Inhibitory Effect of Imetelstat, a Novel Human Telomerase Inhibitor in Diffuse Large B-Cell Lymphoma and Peripheral T-Cell Lymphoma () - Nov 29, 2022 - Abstract #ASH2022ASH_7374;
While in PTCL cell lines, the activity of imetelstat was enhanced when combined with SAHA. In the lymphoma landscape, telomerase may be a therapeutic target for ABC-type DLBCL; the novel telomerase inhibitor Imetelstat may present one of the potential treatment options.
- || imetelstat (GRN163L) / Geron, lenalidomide / Generic mfg.
What do you gents think about imetelstat vs lenalidomide? (Twitter) - Nov 21, 2022
- ||| imetelstat (GRN163L) / Geron
Adverse events: Take those imetelstat injections with u to relieve yourself of clotting risks (Twitter) - Nov 12, 2022
- || imetelstat (GRN163L) / Geron
Is there a section on Imetelstat? (Twitter) - Nov 9, 2022
- || Review, Journal: Anemia in myelofibrosis: current and emerging treatment options. (Pubmed Central) - Nov 5, 2022
This review summarizes current and emerging treatments for anemia in MF, including luspatercept and KER-050 (transforming growth factor-β ligand traps), momelotinib and pacritinib (JAK inhibitors), pelabresib (a bromodomain extra-terminal domain inhibitor), PRM-151 (an antifibrotic agent), imetelstat (a telomerase inhibitor), and navitoclax (a BCL-2/BCL-xL inhibitor). Therapeutic combinations with ruxolitinib may offer another treatment approach.
- imetelstat (GRN163L) / Geron
MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_4422;
P2, P3
Janus Kinase inhibitors (JAKi) ruxolitinib, pacritinib and fedratinib are the FDA-approved treatment options for MF...Patients will be randomized to receive intravenous imetelstat 9.4 mg/kg every 21 days or investigator-selected BAT that may include hydroxyurea, thalidomide, interferon, danazol, hypomethylating agents, chemotherapy, or other non–JAKi-containing therapy as appropriate (Figure 2)...Approximately 180 sites are planned in North and South America, Europe, Middle East, Australia and Asia. The study is actively enrolling.
- imetelstat (GRN163L) / Geron
Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study (ENMCC - R06-R09) - Nov 4, 2022 - Abstract #ASH2022ASH_3671;
P2/3
Of the overall population, attainment of 24-week TI was indicative of a likelihood to achieve TI >1 year. In this ESA-R/R population with a high transfusion burden prior to treatment, a decrease to zero RBC transfusions for a period >1 year represents relief from iron overload and other transfusion-associated complications, and decreased demand on health care resources.
- imetelstat (GRN163L) / Geron, Jakafi (ruxolitinib) / Novartis, Incyte
MYF1001: An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate 1, Intermediate 2 or High-Risk Myelofibrosis (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2572;
P1, P2
Secondary objectives include symptom and spleen response rates at Week 24, progression-free survival, clinical response assessments per modified 2013 International Working Group – Myeloproliferative Neoplasms Research and Treatment criteria, time to and duration of response, reduction in degree of bone marrow fibrosis, and the pharmacokinetics and immunogenicity of imetelstat. The Phase 1 dose-escalation (Part 1) is open for enrollment, with approximately 3 sites planned in North America.
- imetelstat (GRN163L) / Geron
Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia (ENMCC - 343-345) - Nov 4, 2022 - Abstract #ASH2022ASH_1599;
In vivo AML PDX efficacy of imetelstat was partially diminished by liproxstatin-1 treatment...Anthracycline/cytarabine chemotherapy significantly increased ROS levels in a dose-dependent manner in all AML cell lines tested...Pharmacological inhibition of ferroptosis diminishes imetelstat efficacy. These mechanistic insights may be leveraged to develop an optimized therapeutic strategy using oxidative stress-inducing chemotherapy to sensitize leukemia cells to imetelstat providing significantly improved disease control for AML.
- || imetelstat (GRN163L) / Geron
Do you have a view on imetelstat ph3? (Twitter) - Oct 23, 2022
- || imetelstat (GRN163L) / Geron
@DavidSteensma any thoughts on Imetelstat for MDS? How likely is the Imerge ph3 going to work? (Readout soon) (Twitter) - Oct 22, 2022
- | imetelstat (GRN163L) / Geron
Journal: Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma models. (Pubmed Central) - Oct 21, 2022
Our study indicates that telomerase is an actionable target in telomerase-positive neuroblastoma, and demonstrates that combination therapies including telomerase-interacting compounds may improve the efficacy of established cytotoxic drugs. Targeting telomerase may thus represent a therapeutic option in high-risk neuroblastoma patients.
- |||| imetelstat (GRN163L) / Geron, Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
#LLMCongress2022 #leusm @Dr_AmerZeidan: Imetelstat and roxadustat in trials for LR-MDS. (Twitter) - Oct 19, 2022
- || Rytelo (imetelstat) / Geron
New P2 trial: IMpress: Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy (clinicaltrials.gov) - Oct 17, 2022
P2, N=46, Not yet recruiting, Sponsor: GCP-Service International West GmbH
- || imetelstat (GRN163L) / Geron
Fantastic! Let get imetelstat approved (Twitter) - Oct 15, 2022
- || imetelstat (GRN163L) / Geron, Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap, Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Review, Journal: MDS-261 Systematic Literature Review (SLR) to Identify the Burden of Illness and Treatment Effectiveness in ESA-Refractory or Relapsed, Transfusion-Dependent, Low-Risk MDS. (Pubmed Central) - Sep 29, 2022
The continued use of ESAs and HMAs in ESA-r/r LR-MDS demonstrates a high unmet need. New therapies that reduce transfusions and improve durability across RS status may improve HRQoL and outcomes.